KA, Han M et al: Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70:1117. 167. Bul M, Zhu X, Valdagni R et al: Active surveillance for low risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63:597 168. Dall'Era MA, Konety BR, Cowan JE et al: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112:2664. 169. Kakehi Y, Kamoto T, Shiraishi T et al: Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 49 T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008; 38:122. 170. Roemeling S, Roobol MJ, de Vries SH et al: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51: 1244. 171. Barayan GA, Brimo F, Bégin LR et al: Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU Int 2014; 114: E99. 172. Rubio Briones J, Iborra I, Ramírez M et al: Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know. Actas Urol Esp 2014; 38: 559. 173. Godtman RA, Holmberg E, Khatami A et al: Outcome following active surveillance of men with screen detected prostate cancer. Results from the Göteborg randomised population based prostate cancer screening trial. Eur Urol 2013; 63:101. 174. Thomsen FB, Røder MA, Hvarness H et al: Active surveillance can reduce overtreatment in patients with low risk prostate cancer. Dan Med J 2013; 60: A4575. 175. Selvadurai ED, Singhera M, Thomas K et al: Medium term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013; 64:981. 176. Hayes JH, Ollendorf DA, Pearson SD et al: Active surveillance compared with initial treatment for men with low risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373. 177. Bokhorst LP, Lepistö I, Kakehi Y et al: Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. BJU Int 2016; 118:366. 178. Morash C, Tey R, Agbassi C et al: Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 2015; 9: 171. 179. Chen RC, Rumble RB, Loblaw DA et al: Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2016; 34:2182. 180. Schoots IG, Petrides N, Giganti F et al: Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2015; 67:627. 181. American Urological Association and Society of Abdominal Radiology: ProstateMRI and MRI targeted biopsy in patients with prior negative biopsy. American Urological Association 2016; https://www.auanet.org/common/pdf/education/clinical guidance/Consensus Statement Prostate MRI and MRI Targeted Biopsy.pdf 182. American College of Radiology: PI RADS Prostate imaging—reporting and data system. American College of Radiology 2015; https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADS%20V2.pdf 183. Weinreb JC, Barentsz JO, Choyke PL et al: PI RADS Prostate Imaging Reporting and Data System:2015,Version 2. Eur Urol 2016; 69:16. 184. Alchin DR, Murphy D and Lawrentschuk N: Risk factors for Gleason score upgrading following radical prostatectomy: a review of the current literature. Minerva Urol Nefrol 2016; Epub ahead of print. 185. Berglund RK, Masterson TA, Vora KC et al: Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180:1964. 186. Agarwal G, Buethe D, Russell C et al: Long term survival and predictors of disease reclassification in patients on an active surveillance protocol for prostate cancer. Can J Urol 2016; 23: 8215. 187. Iremashvili V, Kava BR, Manoharan M et al: Is it time to revisit the role of prostate specific antigen kinetics in active surveillance for prostate cancer? Urology 2016; 95:139. 188. Popiolek M, Rider JR, Andrén O et al: Natural history of early, localized prostate cancer: a final report from three decades of follow up. Eur Urol 2013; 63:428. 189. Aus G, Hugosson J and Norlén L: Long term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460. 190. Lu Yao GL and Yao SL: Population based study of long term survival in patients with clinically localised prostate cancer. Lancet 1997; 349:906. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 50 191. Chodak GW, Thisted RA, Gerber GS et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330:242. 192. Schroder FH, Hermanek P, Denis L et al: The TNM classification of prostate cancer. Prostate Suppl 1992; 4:129. 193. Whitmore WF Jr.: Natural history and staging of prostate cancer. Urol Clin North Am 1984; 11:205. 194. Yaxley JW, Coughlin GD, Chambers SK et al: Robot assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016 388:1057. 195. Alemozaffar M, Sanda M, Yecies D et al: Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the health professionals follow up study. Eur Urol 2015; 67(3): 432. 196. Krambeck AE, DiMarco DS, Rangel LJ et al: Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot assisted techniques. BJU Int 2009; 103:448. 197. Wallerstedt A, Tyritzis SI, Thorsteinsdottir T et al: Short term results after robot assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. Eur Urol 2015; 67:660. 198. Punnen S, Cowan JE, Chan JM et al: Long term health related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol 2015; 68:600. 199. Schulman CC, Debruyne FMJ, Forster G et al: 4 year follow up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2 3N0M0 prostate cancer. Eur Urol 2000; 38:706. 200. Soloway MS, Pareek K, Sharifi R et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5 year results. J Urol 2002; 167:112. 201. Aus G, Abrahamsson G, Ahlgren G et al: Three month neoadjuvant hormonal therapy before radical prostatectomy: a 7 year follow up of a randomized controlled trial. BJU Int 2002; 90:561. 202. Klotz LH, Goldenberg SL, Jewett MA et al: Long term follow up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791. 203. Pietzak EJ and Eastham JA: Neoadjuvant treatment of high risk, clinically localized prostate cancer prior to radical prostatectomy. Curr Urol Rep 2016; 17: 37. 204. Alemozaffar M, Regan MM, Cooperberg MR et al: Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205. 205. Wright JL, Lin DW, Cowan JE et al: Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis 2008; 11: 67. 206. Brajtbord JS, Punnen S, Cowan JE et al: Age and baseline quality of life at radical prostatectomy Who has the most to lose? J Urol 2014; 192: 396. 207. Le JD, Cooperberg MR, Sadetsky N et al: Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int 2010; 106: 1022. 208. Michl UH, Friedrich MG, Graefen M et al: Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol 2006; 176: 227. 209. Briganti A, Capitanio U, Chun FK et al: Prediction of sexual function after radical prostatectomy. Cancer 2009; 115: 3150. 210. Novara G, Ficarra V, D'Elia C et al: Preoperative criteria to select patients for bilateral nerve sparing robotic assisted radical prostatectomy. J Sex Med 2010; 7:839. 211. Namiki S, Kwan L, Kagawa Singer M et al: Urinary quality of life after prostatectomy or radiation for localized prostate cancer: a prospective longitudinal cross cultural study between Japanese and U.S. men. Urology 2008; 71: 1103. 212. Wei JT, Dunn RL, Marcovich R et al: Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000; 164:744. 213. Mandel P, Graefen M, Michl U et al: The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 2015; 33: 203.e11. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 51 214. Briganti A, Larcher A, Abdollah F et al: Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61:480. 215. Mattei A, Fuechsel FG, Bhatta Dhar N et al: The template of primary landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53:118. 216. Klein EA, Kattan M, Stephenson A et al: How many lymphadenectomies does it take to cure one patient? Eur Urol 2008; 53:13. 217. Bader P, Burkhard FC, Markwalder R et al: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169:849. 218. Allaf ME, Palapattu GS, Trock BJ et al: Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172:1840. 219. Daneshmand S, Quek ML, Stein JP et al: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long term results J Urol 2004; 172:2252. 220. Berglund RK, Sadetsky N, DuChane J et al: Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5 year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 2007; 177: 526. 221. DiMarco DS, Zincke H, SeboTJ et al: The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005; 173:1121. 222. Masterson TA, Bianco FJ, Jr., Vickers AJ et al: The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175:1320. 223. Bhatta Dhar N, Reuther AM, Zippe C et al: No difference in six year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low risk patients with localized prostate cancer. Urology 2004; 63:528. 224. Abdollah F, Schmitges J, Sun M et al: A critical assessment of the value of lymph node dissection at radical prostatectomy: A population based study. Prostate 2011; 71: 1587. 225. Cagiannos I, Karakiewicz P, Eastham JA et al: A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170:1798. 226. Lee HJ and Kane CJ: How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy. Curr Urol Rep 2014; 15:445. 227. Heers H, Laumeier T, Olbert PJ et al: Lymphoceles post radical retropubic prostatectomy: a retrospective evaluation of epidemiology, risk factors and outcome. Urol Int 2015;95:400. 228. Thompson IM Jr, Tangen CM, Paradelo J et al: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296:2329. 229. Feng M, Hanlon AL, Pisansky TM et al: Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1417. 230. Van Cangh PJ, Richard F, Lorge F et al: Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 1998; 159: 164. 231. Mohler JL, Armstrong AJ, Bahnson RR et al: Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016; 14:19. 232. Zaorsky NG, Harrison AS, Trabulsi EJ et al: Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol 2013; 10: 565. 233. Nilsson S, Norlén BJ and Widmark A: A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316. 234. Hsu IC, Yamada Y, Assimos DG et al: ACR Appropriateness Criteria high dose rate brachytherapy for prostate cancer. Brachytherapy 2014; 13: 27. 235. Nguyen PL, Aizer A, Assimos DG et al: ACR Appropriateness Criteria® Definitive External American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 52 Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol 2014; 37:278. 236. Abdel Wahab M, Mahmoud O, Merrick G et al: ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer. J Am Coll Radiol 2012; 9:233. 237. Frank SJ, Arterbery VE, Hsu IC et al: American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011; 10:357. 238. Dirix P, Joniau S, Van den Bergh L et al: The role of elective pelvic radiotherapy in clinically node negative prostate cancer: a systematic review. Radiother Oncol 2014; 110: 45. 239. Hanks GE, Pajak TF, Porter A et al: Radiation Therapy Oncology Group Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92 02. J Clin Oncol 2003; 21: 3972. 240. Roach M 3rd, Hanks G, Thames H Jr. et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965. 241. Asbell SO, Krall JM, Pilepich MV et al: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77 06. Int J Radiat Oncol Biol Phys 1988; 15: 1307. 242. Pommier P, Chabaud S, Lagrange JL et al: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long term survival results of the GETUG 01 randomized study. Int J Radiat Oncol Biol Phys 2016; 96: 759. 243. Nguyen PL: Rethinking the balance of risk and benefit of androgen deprivation therapy for intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2016; 94: 975. 244. Yoon FH, Gardner SL, Danjoux C et al: Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol 2008; 180: 1443. 245. Hegemann NS, Guckenberger M, Belka C et al: Hypofractionated radiotherapy for prostate cancer. Radiat Oncol 2014; 9:275. 246. Dearnaley D, Syndikus I, Sumo G et al: Conventional versus hypofractionated high dose intensity modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012; 13: 43. 247. Wilkins A, Mossop H, Syndikus I et al: Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate risk localised prostate cancer: 2 year patient reported outcomes of the randomised, non inferiority, phase 3 CHHiP trial. Lancet Oncol 2015; 16:1605. 248. Dearnaley D, Syndikus I, Mossop H et al: Conventional versus hypofractionated high dose Intensity modulated radiotherapy for prostate cancer: 5 year outcomes of the randomised, non inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17:1047. 249. Pham YD, Kittel JA, Reddy CA et al: Outcomes for prostate glands >60 cc treated with low dose rate brachytherapy. Brachytherapy 2016; 15: 163. 250. Davis BJ, Horwitz EM, Lee WR et al: American Brachytherapy Society consensus guidelines for transrectal ultrasound guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6. 251. Yamoah K and Johnstone PA: Proton beam therapy: clinical utility and current status in prostate cancer. Onco Targets Ther 2016;9:5721. 252. Sheets NC, Goldin GH, Meyer AM et al. Intensity modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307:1611. 253. Hahn C, Kavanagh B, Bhatnagar A et al: Choosing wisely: the American Society for Radiation Oncology's top 5 list. Pract Radiat Oncol 2014; 4:349. 254. Robinson JW, Donnelly BJ, Siever JE et al: A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009; 115:4695. Copyright © 2017 American Urological Association Education and Research, Inc.® American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Clinically Localized Prostate Cancer 53 255. Baust JG, Gage AA, Klossner D et al: Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Streat 2007; 6:97. 256. Larson TR, Rrobertson DW, Corica A et al: In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology 2000; 55:547. 257. Williams SB, Lei Y, Nguyen PL et al: Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int 2012; 110:E92. 258. Malcolm JB, Fabrizio MD, Barone BB et al: Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010; 183:1822. 259. Lambert EH, Bolte K, Masson P et al: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007; 69:1117. 260. Chin JL, Ng CK, Touma NJ et al: Randomized trial comparing cryoablation and external beam radiotherapy for T2C T3B prostate cancer. Prostate Cancer Prostatic Dis 2008; 11:40. 261. Mearini L, D’Urso L, Collura D et al: High intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with long term follow up. Scandinavian J Urol 2015;49: 267. 262. Sumitomo M, Hayashi M, Watanabe T et al: Efficacy of short term androgen deprivation with high intensity focused ultrasound in the treatment of prostate cancer in Japan. Urology 2008; 72:1335. 263. Donaldson IA, Alonzi R, Barratt D et al: Focal therapy: patients, interventions, and outcomes a report from a consensus meeting. Eur Urol 2015; 67:771. 264. Kirkham AP, Emberton M, Hoh IM et al: MR imaging of prostate after treatment with high intensity focused ultrasound. Radiology 2008; 246:833. 265. Boutier R, Girouin N, Cheikh AB et al: Location of residual cancer after transrectal high intensity focused ultrasound ablation for clinically localized prostate cancer. BJU Int 2011; 108:1776. 266. Vallancien G, Prapotnich D, Cathelineau X et al: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004; 171: 2265. 267. Noguchi M, Stamey TA, McNeal JE et al: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170:459. 268. Capogrosso P, Ventimiglia E, Serino A et al: Orgasmic dysfunction after robot assisted versus open radical prostatectomy. Eur Urol 2016; 70: 223. 269. Schwartz EJ and Lepor H: Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms. J Urol 1999; 161:1185. 270. Giberti C, Chiono L, Gallo F et al: Radical retropubic prostatectomy versus brachytherapy for low risk prostatic cancer: a prospective study. World J Urol 2009; 27:607. 271. Chang P, Regan MM, Ferrer M et al: Relief of urinary symptom burden after primary prostate cancer treatment. J Urol 2016; 197: 376. 272. Jarosek SL, Virnig BA, Chu H et al: Propensity weighted long term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol 2015; 67: 273. 273. Ferrer M, Guedea F, Suarez JF et al: Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow up. Radiother Oncol 2013; 108:306. 274. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591. 275. Siegel RL, Miller KD and Jemal Ahmedin: Cancer statistics 2016. CA Cancer J Clin 2016; 66: 7. 276. Prostate Calculator 2017; http://www.prostatecalculator.org/. 277. Memorial Sloan Kettering Cancer Center: Prostate cancer nomograms. 2017; https://www.mskcc.org/nomograms/prostate. 278. Fox Chase Cancer Center: Nomograms. 2010; http://labs.fccc.edu/nomograms/nomogram.php?id=29&audience=1&status=1, American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 54 279. Levy DA, Pisters LL and Jones JS: Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009; 182:931. 280. Levy DA, Ross AE, ElShafei et al: Definition of biochemical success following primary whole gland prostate cryoablation. J Urol 2014; 192:1380. 281. Ross AE, Den RB, Yousefi K et al: Efficacy of post operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 2016; 19: 277. 282. Freedland SJ, Choeurgn V, Howard L et al: Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. Eur Urol 2016; 70: 588. 283. Den RB, Yousefi K, Trabulsi EJ et al: Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015; 33: 944. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 55 Localized Prostate Cancer Panel, Consultants and Staff Martin G. Sanda, MD (Chair) The Emory Clinic, Inc. Atlanta, GA Jeffrey A. Cadeddu, MD (Vice Chair) UT Southwestern Dallas, TX Ronald C. Chen, MD, MPH University of North Carolina at Chapel Hill Chapel Hill, NC Tony Crispino (Patient Advocate) UsTOO Las Vegas Las Vegas, NV Stephen J. Freedland, MD Vedars Sinai Medical Center Los Angeles, CA Kirsten Greene, MD University of California San Francisco San Francisco, CA Laurence H. Klotz, MD Sunnybrook Health Sciences Centre Ontario, Canada Danil V. Makarov, MD NYU Langone Medical Center New York, NY Joel B. Nelson, MD University of Pittsburgh Medical Center Pittsburgh, PA George Rodrigues, MD, PhD London Health Sciences Centre Ontario, Canada Howard M. Sandler, MD Cedars Sinai Medical Center Los Angeles, CA Mary Ellen Taplin, MD Dana Farber Cancer Institute Boston. MA Consultants James Reston, PhD Staff Heddy Hubbard, PhD, MPH, RN, FAAN Abid Khan, MHS, MPP Erin Kirkby, MS Shalini Selvarajah, MD Nenellia K. Bronson, MA Leila Rahimi Brooke Bixler, MPH CONFLICT OF INTEREST DISCLOSURES All panel members completed COI disclosures. Disclosures listed include both topic and non topic related relationships. Consultant/Advisor: Martin G. Sanda, Movember, Prostate Cancer Foundation; Jeffrey A. Cadeddu, Levita Magnetics; Stephen J. Freedland, Dendreon, Medication, Janssen, Bayer, Astellas, Sanofi, ProteoMediX, Parallel 6, MDxHealth, Oncell MDx Laurence H. Klotz, Ferring, Amgen, Profound Medical; Danil Makarov, Castlight Health, Center for Devices and Radiological Health (FDA); Howard M. Sandler, Eviti; Mary Ellen Taplin, Medivation, Janssen, Tokai, Bayer, Dendreon, Sanofi Meeting Participant or Lecturer: Stephen J. Freedland, Janssen, Astellas; Laurence H. Klotz, Astellas, Medivation, Abbvie, Janssen, Profound Medical; Howard M. Sandler, Janssen, Sanofi Scientific Study or Trial: Martin G. Sanda, Movember, Prostate Cancer Foundation; Jeffrey A. Cadeddu, Levita Magnetics; Ronald C. Chen, Accuray Inc.; Stephen J. Freedland, GSK, Dendreon, Janssen, Bayer, Myriad, GenomeDX, Metabolon, MDxHealth, Progenika, Oncell MDx; Laurence H. Klotz, Ferring, Amgen, Astellas, Medivation, Abbvie, Janssen, Profound Medical; Mary Ellen Taplin, Medivation, Tokai, Bayer, Genetech Leadership Position: George Rodrigues, ASTRO; Investment Interest: Jeffrey A. Cadeddu, Titan Medical Inc, Transenterix; Mary Ellen Taplin, Janssen Health Publishing: George Rodrigues, Demos Medical Publishers; Howard M. Sandler, Caribou Publishing American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 56 Peer Reviewers We are grateful to the persons listed below who contributed to the Guideline by providing comments during the peer review process. Their reviews do not necessarily imply endorsement of the Guideline. Peter C. Albertsen, MD Andrew Armstrong, MD Richard J. Babaian, MD Rodney Breau, MD Joseph L. Chin, MD Peter E. Clark, MD Matthew R. Cooperberg, MD Anthony V. D’Amico, MD Adam Dicker, MD James A. Eastham, MD Phillip G. Febbo, MD Antonio Finelli, MD David A. Ginsberg, MD B. Mayer Grob, MD Frederick A. Gulmi, MD Blake D. Hamilton, MD Celestia S. Higano, MD Jim C. Hu, MD Suneil Jain, MD Christopher J. Kane, MD Melissa R. Kaufman, MD Louis R. Kavoussi, MD Adam S. Kibel, MD Bridget F. Koontz, MD Deborah J. Lightner, MD Andrew Loblaw, MD Stacy Loeb, MD Viraj A. Master Joshua J. Meeks, MD, PhD Drew Moghanaki, MD Matthew E. Nielsen, MD David F. Penson, MD Thomas J. Polascik, MD Glenn M. Preminger, MD Ashley E. Ross, MD Edward M. Schaeffer, MD Roger E. Schultz, MD Alan W. Shindel, MD Kirill Shiranov, MD Chandru P. Sundaram, MD Christopher D. Tessier, MD J. Brantley Thrasher, MD J. Stuart Wolf, Jr., MD DISCLAIMER This document was written by the Clinically Localized Prostate Cancer Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2014. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair. Membership of the Panel included specialists in urology/medical oncology/radiation oncology with specific expertise on this disorder. The mission of the Panel was to develop recommendations that are analysis based or consensus based, depending on Panel processes and available data, for optimal clinical practices in the treatment of clinically localized prostate cancer. Funding of the Panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the Panel provides an ongoing conflict of interest disclosure to the AUA. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to